Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine ... disease and pneumonia caused by Streptococcus pneumoniae in people aged ...

The 21-valent product – formerly known as V116 – covers a wider range of Streptococcus pneumoniae serotypes than any of MSD’s earlier vaccines and eight that are not covered by any other ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

For analyzing alterations in membrane potential, control and AA-treated bacteria were resuspended in 1 ml of PBS containing 30 μM of the potentiometric dye DiOC2(3) (BacLight Membrane Potential Kit, ...

The burden of disease is predominately attributable to a small number of the more than 100 identified serotypes of a Streptococcus pneumoniae bacteria. Invasive pneumococcal disease is most common in ...

For the first eight mice in the study, 40 µL of the BHI culture were then plated on supplemented BHI agar plates and cultured under the respective atmospheric condition for an additional 48 hours, and ...

In addition, after endothelial damage and turbulent blood flow, inflammatory processes stimulate the clotting system, leading to the deposition of fibrin and the creation of an insoluble clot of ...